Regeneron Pharmaceuticals (REGN) R&D In Process (2021 - 2026)
Regeneron Pharmaceuticals' quarterly R&D In Process came in at $101.9 million in Q1 2026, up 728.46% year-on-year from $12.3 million in Q1 2025, and up 444.92% quarter-over-quarter from $18.7 million in Q4 2025.
Regeneron Pharmaceuticals has reported R&D In Process for 6 years, with the latest figure at $101.9 million in Q1 2026.
- For the quarter ending Q1 2026, R&D In Process rose 728.46% year-over-year to $101.9 million; the trailing twelve-month figure through Mar 2026 stood at $213.7 million (up 101.22% YoY), and the FY2025 full-year result was $124.1 million, up 22.87% from the prior year.
- R&D In Process for Q1 2026 stood at $101.9 million, up from $18.7 million in the prior quarter.
- The five-year high for R&D In Process was $197.0 million in Q2 2022, with the low at $7.1 million in Q1 2024.
- Average R&D In Process over 5 years is $51.2 million, with a median of $30.0 million recorded in 2022.
- Year-over-year, R&D In Process sank 87.34% in 2024 and jumped 728.46% in 2026.
- Tracing REGN's R&D In Process over 5 years: stood at $30.0 million in 2022, then changed by 0.0% to $30.0 million in 2023, then slumped by 54.0% to $13.8 million in 2024, then surged by 35.51% to $18.7 million in 2025, then soared by 444.92% to $101.9 million in 2026.
- The last three R&D In Process figures came in at $101.9 million (Q1 2026), $18.7 million (Q4 2025), and $83.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101.90 Mn |
| Dec 31, 2025 | 18.70 Mn |
| Sep 30, 2025 | 83.10 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 12.30 Mn |
| Dec 31, 2024 | 13.80 Mn |
| Sep 30, 2024 | 56.20 Mn |
| Jun 30, 2024 | 23.90 Mn |
| Mar 31, 2024 | 7.10 Mn |
| Dec 31, 2023 | 30.00 Mn |
| Sep 30, 2023 | 100.00 Mn |
| Mar 31, 2023 | 56.10 Mn |
| Dec 31, 2022 | 30.00 Mn |
| Jun 30, 2022 | 197.00 Mn |
| Mar 31, 2022 | 28.10 Mn |
| Dec 31, 2021 | 48.00 Mn |